{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CIP2A", "Cucurbitacin B", "EGFR", "gefitinib-resistant NSCLC", "lysosomal degradation"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30759826", "DateCompleted": {"Year": "2019", "Month": "05", "Day": "30"}, "DateRevised": {"Year": "2020", "Month": "02", "Day": "25"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "02", "Day": "12"}], "Language": ["eng"], "ELocationID": ["647", "10.3390/molecules24030647"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "24", "Issue": "3", "PubDate": {"Year": "2019", "Month": "Feb", "Day": "12"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.", "Abstract": {"AbstractText": ["Non-small cell lung cancer (NSCLC) patients carrying an epidermal growth factor receptor (EGFR) mutation are initially sensitive to EGFR-tyrosine kinase inhibitors (TKIs) treatment, but soon develop an acquired resistance. The treatment effect of EGFR-TKIs-resistant NSCLC patients still faces challenges. Cucurbitacin B (CuB), a triterpene hydrocarbon compound isolated from plants of various families and genera, elicits anticancer effects in a variety of cancer types. However, whether CuB is a viable treatment option for gefitinib-resistant (GR) NSCLC remains unclear. Here, we investigated the anticancer effects and underlying mechanisms of CuB. We report that CuB inhibited the growth and invasion of GR NSCLC cells and induced apoptosis. The inhibitory effect of CuB occurred through its promotion of the lysosomal degradation of EGFR and the downregulation of the cancerous inhibitor of protein phosphatase 2A/protein phosphatase 2A/Akt (CIP2A/PP2A/Akt) signaling axis. CuB and cisplatin synergistically inhibited tumor growth. A xenograft tumor model indicated that CuB inhibited tumor growth in vivo. Immunohistochemistry results further demonstrated that CuB decreased EGFR and CIP2A levels in vivo. These findings suggested that CuB could suppress the growth and invasion of GR NSCLC cells by inducing the lysosomal degradation of EGFR and by downregulating the CIP2A/PP2A/Akt signaling axis. Thus, CuB may be a new drug candidate for the treatment of GR NSCLC."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. LiuPF_001@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. LiuPF_001@163.com."}], "LastName": "Liu", "ForeName": "Pengfei", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. xiangyc4026@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. xiangyc4026@163.com."}], "LastName": "Xiang", "ForeName": "Yuchen", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. liuxw1110@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. liuxw1110@163.com."}], "LastName": "Liu", "ForeName": "Xuewen", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. zhangte519@163.com."}], "LastName": "Zhang", "ForeName": "Te", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. yangr0512@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. yangr0512@163.com."}], "LastName": "Yang", "ForeName": "Rui", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. sener_chen@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. sener_chen@163.com."}], "LastName": "Chen", "ForeName": "Sen", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. xuli103028@sina.com."}], "LastName": "Xu", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. 18064081841@163.com."}], "LastName": "Yu", "ForeName": "Qingqing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. zhaohz07@163.com."}], "LastName": "Zhao", "ForeName": "Huzi", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. zl_19820321@163.com."}], "LastName": "Zhang", "ForeName": "Liang", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. ying_liu1002@163.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. ying_liu1002@163.com."}, {"Identifier": [], "Affiliation": "Hubei Key Laboratory of Wudang Local Chinese Medicine Research and Institute of Medicinal Chemistry, Hubei University of Medicine, Shiyan 442000, China. ying_liu1002@163.com."}], "LastName": "Liu", "ForeName": "Ying", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan 442000, China. siyuan138@126.com."}, {"Identifier": [], "Affiliation": "Laboratory of Molecular Target Therapy of Cancer, Biomedical Research Institute, Hubei University of Medicine, Shiyan 442000, China. siyuan138@126.com."}], "LastName": "Si", "ForeName": "Yuan", "Initials": "Y"}], "GrantList": [{"GrantID": "81802387", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "17Y01 and 18Y13", "Agency": "the Scientific and Technological Project of Shiyan City of Hubei Province", "Country": ""}, {"GrantID": "2018QDJZR03, 2017QDJZR12, 2018QDJZR27", "Agency": "the Faculty Development grants from Hubei University of Medicine", "Country": ""}, {"GrantID": "201810929012 and 201810929056", "Agency": "the National Training Program of Innovation and Entrepreneurship for Undergraduates", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Autoantigens"}, {"RegistryNumber": "0", "NameOfSubstance": "CIP2A protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Intracellular Signaling Peptides and Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Membrane Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Triterpenes"}, {"RegistryNumber": "0115W5MABF", "NameOfSubstance": "cucurbitacin B"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}, {"RegistryNumber": "EC 3.1.3.16", "NameOfSubstance": "Protein Phosphatase 2"}, {"RegistryNumber": "S65743JHBS", "NameOfSubstance": "Gefitinib"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "A549 Cells"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["metabolism"], "DescriptorName": "Autoantigens"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Down-Regulation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Drug Resistance, Neoplasm"}, {"QualifierName": ["metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Gefitinib"}, {"QualifierName": [], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Intracellular Signaling Peptides and Proteins"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Lysosomes"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["metabolism"], "DescriptorName": "Membrane Proteins"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["metabolism"], "DescriptorName": "Protein Phosphatase 2"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Triterpenes"}], "CoiStatement": "The authors have no conflicts of interest to declare."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Xiao X., He Z., Cao W., Cai F., Zhang L., Huang Q., Fan C., Duan C., Wang X., Wang J., et al. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int. J. Oncol. 2016;48:2608\u20132618. doi: 10.3892/ijo.2016.3488.", "ArticleIdList": ["10.3892/ijo.2016.3488", "27082429"]}, {"Citation": "Lopez Sambrooks C., Baro M., Quijano A., Narayan A., Cui W., Greninger P., Egan R., Patel A., Benes C.H., Saltzman W.M., et al. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78:5094\u20135106. doi: 10.1158/0008-5472.CAN-18-0505.", "ArticleIdList": ["10.1158/0008-5472.CAN-18-0505", "PMC6125176", "30026325"]}, {"Citation": "Kim J.H., Nam B., Choi Y.J., Kim S.Y., Lee J.E., Sung K.J., Kim W.S., Choi C.M., Chang E.J., Koh J.S., et al. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation. Cancer Res. 2018;78:4482\u20134496. doi: 10.1158/0008-5472.CAN-18-0117.", "ArticleIdList": ["10.1158/0008-5472.CAN-18-0117", "29945964"]}, {"Citation": "Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., Meyerson M., Eck M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA. 2008;105:2070\u20132705. doi: 10.1073/pnas.0709662105.", "ArticleIdList": ["10.1073/pnas.0709662105", "PMC2538882", "18227510"]}, {"Citation": "Liu X., Cao W., Qin S., Zhang T., Zheng J., Dong Y., Ming P., Cheng Q., Lu Z., Guo Y., et al. Overexpression of CIP2A is associated with poor prognosis in multiple myeloma. Signal Transduct. Target. 2017;2:17013. doi: 10.1038/sigtrans.2017.13.", "ArticleIdList": ["10.1038/sigtrans.2017.13", "PMC5661621", "29263916"]}, {"Citation": "Li S., Feng T.-T., Guo Y., Yu X., Huang Q., Zhang L., Tang W., Liu Y. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy. Oncol. Lett. 2016;12:5370\u20135376. doi: 10.3892/ol.2016.5374.", "ArticleIdList": ["10.3892/ol.2016.5374", "PMC5228275", "28101248"]}, {"Citation": "Ji J., Zhen W., Si Y., Ma W., Zheng L., Li C., Zhang Y., Qin S., Zhang T., Liu P., et al. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer. Cancer Biomark. 2018;21:307\u2013316. doi: 10.3233/CBM-170416.", "ArticleIdList": ["10.3233/CBM-170416", "29103022"]}, {"Citation": "Qin S., Li J., Si Y., He Z., Zhang T., Wang D., Liu X., Guo Y., Zhang L., Li S., et al. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. Mol. Carcinog. 2018;57:687\u2013699. doi: 10.1002/mc.22789.", "ArticleIdList": ["10.1002/mc.22789", "29393542"]}, {"Citation": "Jin L., Si Y., Hong X., Liu P., Zhu B., Yu H., Zhao X., Qin S., Xiong M., Liu Y., et al. Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A. Int. J. Oncol. 2018;52:1569\u20131578. doi: 10.3892/ijo.2018.4323.", "ArticleIdList": ["10.3892/ijo.2018.4323", "29568959"]}, {"Citation": "Liu Z., Ma L., Wen Z.S., Hu Z., Wu F.Q., Li W., Liu J., Zhou G.B. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis. 2014;35:905\u2013914. doi: 10.1093/carcin/bgt395.", "ArticleIdList": ["10.1093/carcin/bgt395", "PMC4319067", "24293411"]}, {"Citation": "Ma L., Wen Z.S., Liu Z., Hu Z., Ma J., Chen X.Q., Liu Y.Q., Pu J.X., Xiao W.L., Sun H.D., et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS ONE. 2011;6:e20159. doi: 10.1371/journal.pone.0020159.", "ArticleIdList": ["10.1371/journal.pone.0020159", "PMC3105001", "21655278"]}, {"Citation": "Junttila M.R., Puustinen P., Niemela M., Ahola R., Arnold H., Bottzauw T., Ala-aho R., Nielsen C., Ivaska J., Taya Y., et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51\u201362. doi: 10.1016/j.cell.2007.04.044.", "ArticleIdList": ["10.1016/j.cell.2007.04.044", "17632056"]}, {"Citation": "De P., Carlson J., Leyland-Jones B., Dey N. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands. Oncotarget. 2014;5:4581\u20134602. doi: 10.18632/oncotarget.2127.", "ArticleIdList": ["10.18632/oncotarget.2127", "PMC4148086", "25015035"]}, {"Citation": "Perrotti D., Neviani P. Protein phosphatase 2A: A target for anticancer therapy. Lancet. Oncol. 2013;14:e229\u2013e238. doi: 10.1016/S1470-2045(12)70558-2.", "ArticleIdList": ["10.1016/S1470-2045(12)70558-2", "PMC3913484", "23639323"]}, {"Citation": "Seshacharyulu P., Pandey P., Datta K., Batra S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335:9\u201318. doi: 10.1016/j.canlet.2013.02.036.", "ArticleIdList": ["10.1016/j.canlet.2013.02.036", "PMC3665613", "23454242"]}, {"Citation": "Huang C.Y., Hung M.H., Shih C.T., Hsieh F.S., Kuo C.W., Tsai M.H., Chang S.S., Hsiao Y.J., Chen L.J., Chao T.I., et al. Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation. J. Pharmacol. Exp. Ther. 2018;366:410\u2013421. doi: 10.1124/jpet.118.249102.", "ArticleIdList": ["10.1124/jpet.118.249102", "29914877"]}, {"Citation": "Sangodkar J., Farrington C.C., McClinch K., Galsky M.D., Kastrinsky D.B., Narla G. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283:1004\u20131024. doi: 10.1111/febs.13573.", "ArticleIdList": ["10.1111/febs.13573", "PMC4803620", "26507691"]}, {"Citation": "Chan K.T., Meng F.Y., Li Q., Ho C.Y., Lam T.S., To Y., Lee W.H., Li M., Chu K.H., Toh M. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 2010;294:118\u2013124. doi: 10.1016/j.canlet.2010.01.029.", "ArticleIdList": ["10.1016/j.canlet.2010.01.029", "20153103"]}, {"Citation": "Cai F., Zhang L., Xiao X., Duan C., Huang Q., Fan C., Li J., Liu X., Li S., Liu Y. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells. Oncol. Rep. 2016;36:1180\u20131186. doi: 10.3892/or.2016.4892.", "ArticleIdList": ["10.3892/or.2016.4892", "27350399"]}, {"Citation": "Shukla S., Khan S., Kumar S., Sinha S., Farhan M., Bora H.K., Maurya R., Meeran S.M. Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis. Cancer Prev. Res. 2015;8:552\u2013562. doi: 10.1158/1940-6207.CAPR-14-0286.", "ArticleIdList": ["10.1158/1940-6207.CAPR-14-0286", "25813524"]}, {"Citation": "Guo J., Zhao W., Hao W., Ren G., Lu J., Chen X. Cucurbitacin B induces DNA damage, G2/M phase arrest, and apoptosis mediated by reactive oxygen species (ROS) in leukemia K562 cells. Anti-Cancer Agents Med. Chem. 2014;14:1146\u20131153. doi: 10.2174/1871520614666140601220915.", "ArticleIdList": ["10.2174/1871520614666140601220915", "24893803"]}, {"Citation": "Cao W., Liu Y., Zhang R., Zhang B., Wang T., Zhu X., Mei L., Chen H., Zhang H., Ming P., et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci. Rep. 2015;5:8477. doi: 10.1038/srep08477.", "ArticleIdList": ["10.1038/srep08477", "PMC4499885", "26166037"]}, {"Citation": "Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT Method. Methods. 2001;25:402\u2013408. doi: 10.1006/meth.2001.1262.", "ArticleIdList": ["10.1006/meth.2001.1262", "11846609"]}, {"Citation": "Liu H., Gu Y., Wang H., Yin J., Zheng G., Zhang Z., Lu M., Wang C., He Z. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget. 2015;6:14913\u201314925. doi: 10.18632/oncotarget.3818.", "ArticleIdList": ["10.18632/oncotarget.3818", "PMC4558125", "25945834"]}, {"Citation": "Wen J., Fu J., Ling Y., Zhang W. MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer. Oncotarget. 2016;7:9118\u20139134. doi: 10.18632/oncotarget.7001.", "ArticleIdList": ["10.18632/oncotarget.7001", "PMC4891030", "26824318"]}, {"Citation": "Gao J., Liu X., Yang F., Liu T., Yan Q., Yang X. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget. 2015;6:27187\u201327198. doi: 10.18632/oncotarget.4551.", "ArticleIdList": ["10.18632/oncotarget.4551", "PMC4694982", "26356670"]}, {"Citation": "Yang X.S., Liu S.A., Liu J.W., Yan Q. Fucosyltransferase IV enhances expression of MMP-12 stimulated by EGF via the ERK1/2, p38 and NF-\u03baB pathways in A431 cells. Asian Pac. J. Cancer Prev. 2012;13:1657\u20131662. doi: 10.7314/APJCP.2012.13.4.1657.", "ArticleIdList": ["10.7314/APJCP.2012.13.4.1657", "22799384"]}, {"Citation": "Rincon R., Cristobal I., Zazo S., Arpi O., Menendez S., Manso R., Lluch A., Eroles P., Rovira A., Albanell J., et al. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget. 2015;6:4299\u20134314. doi: 10.18632/oncotarget.3012.", "ArticleIdList": ["10.18632/oncotarget.3012", "PMC4414191", "25726524"]}, {"Citation": "Feng T., Cao W., Shen W., Zhang L., Gu X., Guo Y., Tsai H.-I., Liu X., Li J., Zhang J., et al. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget. 2017;8:329\u2013344. doi: 10.18632/oncotarget.13393.", "ArticleIdList": ["10.18632/oncotarget.13393", "PMC5352123", "27861147"]}, {"Citation": "Kausar H., Munagala R., Bansal S.S., Aqil F., Vadhanam M.V., Gupta R.C. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: Identification of intracellular thiols as critical targets. Cancer Lett. 2013;332:35\u201345. doi: 10.1016/j.canlet.2013.01.008.", "ArticleIdList": ["10.1016/j.canlet.2013.01.008", "23340170"]}, {"Citation": "Shukla S., Sinha S., Khan S., Kumar S., Singh K., Mitra K., Maurya R., Meeran S.M. Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/\u03b2-catenin signaling axis. Sci. Rep. 2016;6:21860. doi: 10.1038/srep21860.", "ArticleIdList": ["10.1038/srep21860", "PMC4764833", "26905250"]}, {"Citation": "Khan N., Jajeh F., Khan M.I., Mukhtar E., Shabana S.M., Mukhtar H. Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells. Carcinogenesis. 2017;38:184\u2013195. doi: 10.1093/carcin/bgw124.", "ArticleIdList": ["10.1093/carcin/bgw124", "PMC6075515", "27881463"]}, {"Citation": "Pritchard V.L., Dimond L., Harrison J.S., Vel\u00e1zquez C.C.S., Zieba J.T., Burton R.S., Edmands S. Interpopulation hybridization results in widespread viability selection across the genome in Tigriopus californicus. BMC Genet. 2011;12:54. doi: 10.1186/1471-2156-12-54.", "ArticleIdList": ["10.1186/1471-2156-12-54", "PMC3138442", "21639918"]}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Mao J., Ma L., Shen Y., Zhu K., Zhang R., Xi W., Ruan Z., Luo C., Chen Z., Xi X., et al. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. Cell Death Dis. 2018;9:963. doi: 10.1038/s41419-018-0998-7.", "ArticleIdList": ["10.1038/s41419-018-0998-7", "PMC6147786", "30237564"]}, {"Citation": "Binshtok U., Sprinzak D. The Domino Effect in EGFR-ERK Signaling. Dev. Cell. 2018;46:128\u2013130. doi: 10.1016/j.devcel.2018.06.021.", "ArticleIdList": ["10.1016/j.devcel.2018.06.021", "30016615"]}, {"Citation": "Cha G., Xu J., Xu X., Li B., Lu S., Nanding A., Hu S., Liu S. High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis. Oncotargets Ther. 2017;10:5907\u20135914. doi: 10.2147/OTT.S148250.", "ArticleIdList": ["10.2147/OTT.S148250", "PMC5731340", "29276394"]}, {"Citation": "Huang Q., Qin S., Yuan X., Zhang L., Ji J., Liu X., Mai W., Zhang Y., Liu P., Sun Z., et al. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Oncol. Rep. 2017;38:598\u2013606. doi: 10.3892/or.2017.5667.", "ArticleIdList": ["10.3892/or.2017.5667", "28560452"]}, {"Citation": "Liu X., Sun Z., Deng J., Liu J., Ma K., Si Y., Zhang T., Feng T., Liu Y., Tan Y. Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer. Int. J. Oncol. 2018;53:1279\u20131288. doi: 10.3892/ijo.2018.4464.", "ArticleIdList": ["10.3892/ijo.2018.4464", "29956727"]}]}], "History": [{"Year": "2018", "Month": "12", "Day": "10"}, {"Year": "2019", "Month": "1", "Day": "27"}, {"Year": "2019", "Month": "2", "Day": "1"}, {"Year": "2019", "Month": "2", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "2", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "31", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "2", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["30759826", "PMC6384961", "10.3390/molecules24030647", "molecules24030647"]}}]}